HONG KONG -- (Marketwire) -- 05/24/12 -- This morning, www.MarketFoundations.com announced new reports highlighting Vertex Pharmaceuticals Incorporated (VRTX) and Huntington Bancshares Incorporated (HBAN). Free research downloads are available at www.MarketFoundations.com/index.php?coa=VRTX&cob=HBAN.
Economic fundamentals leading into 2012 have set a generally positive pace with GDP growth likely to pick up through the coming year. However, there are several important caveats to note as the world economy continues to face headwinds and risks weigh to the downside. Positive outlooks are conditional on fiscal policy in payroll taxes and unemployment insurance benefits and upon the easing of the European debt situation. A repeat of volatility experience in 2011 is likely in 2012, as perceptions about the strength of the U.S. economy and the euro zone will vary over time as events unfold.
Despite the current situation, our team continues to identify high momentum situations with growth potential -- there remains strong opportunity within careful discretion.
Market Foundations is releasing new coverage on Vertex Pharmaceuticals Incorporated for its current position within the healthcare industry. Vertex Pharmaceuticals Incorporated (Vertex) is in the business of discovering, developing, manufacturing and commercializing small molecule drugs for the treatment of serious diseases. The full research report on Vertex Pharmaceuticals Incorporated (VRTX) is available here: www.MarketFoundations.com/index.php?coa=VRTX.
Market Foundations has released research on Huntington Bancshares Incorporated for its changing role within the financial industry. Huntington Bancshares Incorporated (Huntington) is a multi-state diversified regional bank holding company. The full research report on Huntington Bancshares Incorporated (HBAN) is available here: www.MarketFoundations.com/index.php?cob=HBAN.
About Market Foundations
By providing members with financial information services, we provide the foundation investors need to build investing intelligence. The difference between consistently making good investments or bad investments is nothing more than the right information at the right time.
|Fri, May 17, 2013|
|Vertex Calls for Redemption of $400 Million in Convertible Senior Subordinated Notes Due 2015 - Business Wire|
|Thu, May 09, 2013|
|Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences - Business Wire|
|Fri, May 03, 2013|
|Free Research Reports on AVEO, CXO, MWW and VRTX Issued by the Paragon Report - Marketwired|
|Tue, Apr 30, 2013|
|Vertex Reports First Quarter 2013 Financial Results and Reviews Recent Progress in Development Programs for Cystic Fibrosis and Hepatitis C - Business Wire|
|Wed, Apr 24, 2013|
|Vertex Announces New Data that Showed High Viral Cure Rates with a Total of 12 and 24 Weeks of Telaprevir Combination Treatment Among People with Genotype 1 Hepatitis C Who Have the IL28B CC Genotype - Business Wire|
|More Press Releases|